ClinicalTrials.gg

Program

Palovarotene

Also written as “Palovarotene dose level 1”, “Palovarotene dose level 2” and “Palovarotene dose level 3”.

Its studies are mostly in Myositis Ossificans · Dry Eye Syndromes, led by Ipsen.

Furthest: phase 3, since Oct 9, 201710 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ipsen100 open or runningphase 3since Oct 9, 2017Jul 13, 2014none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 13, 2014First study: phase 2 study in Myositis OssificansFirst studyNCT02190747 · 40 enrolled · United States, France, United Kingdom
  2. Oct 26, 2014Phase 2 study in Myositis OssificansNCT02279095 · 58 enrolled · United States, Argentina, Australia and more
  3. Aug 6, 2015Phase 2 study in Myositis OssificansNCT02521792 · 6 enrolled · United States
  4. Oct 9, 2017Phase 3 study in Myositis OssificansNCT03312634 · 107 enrolled · United States, Argentina, Australia and more
  5. Oct 11, 2017Phase 2 study in Exostoses, Multiple HereditaryNCT03442985 · 193 enrolled · United States, Australia, Belgium and more
  6. Feb 18, 2021Phase 1 study in Dry Eye SyndromesNCT04762355 · 48 enrolled · Canada
  7. Apr 1, 20212 phase 1 studiesNCT04829786, NCT04829773
  8. Aug 25, 2021Phase 3 study in Myositis OssificansNCT05027802 · 61 enrolled · United States, Argentina, Australia and more
  9. Mar 24, 2025Phase 1 study in Hepatic ImpairmentNCT06908954 · 31 enrolled · United States

TargetBeta

RARG →read by rule
“Retinoic acid receptor gamma agonist”ChEMBL 37, by rule

Other programs on RARG

ProgramCompanyFurthest phaseStudies
trifaroteneruleGalderma Groupphase 413

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06908954Hepatic Impairment · United States1CompletedFeb 6, 202631
NCT05027802Myositis Ossificans · United States, Argentina, Australia and more3CompletedNov 30, 202461
NCT04829786FOP1CompletedOct 23, 201518
NCT04829773Myositis Ossificans · United States1CompletedMar 29, 201948
NCT04762355Dry Eye Syndromes · Canada1CompletedJan 3, 201948
NCT03442985Exostoses, Multiple Hereditary · United States, Australia, Belgium and more2TerminatedMar 24, 2020193
NCT03312634Myositis Ossificans · United States, Argentina, Australia and more3CompletedJan 24, 2020107
NCT02521792Myositis Ossificans · United States2TerminatedAug 4, 20166
NCT02279095Myositis Ossificans · United States, Argentina, Australia and more2CompletedSep 20, 202258
NCT02190747Myositis Ossificans · United States, France, United Kingdom2CompletedMay 23, 201640

How it is read

Names in the registry

  • “Palovarotene”, 9 entries
  • “Palovarotene dose level 1”, 1 entry
  • “Palovarotene dose level 2”, 1 entry
  • “Palovarotene dose level 3”, 1 entry
  • “Palovarotene dose level 4”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.